• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, January 16, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Science

Diagnosis of Alzheimer’s disease: Llama antibodies detect cerebral lesions

Bioengineer by Bioengineer
November 3, 2016
in Science
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: © Institut Pasteur

The major challenge facing physicians treating Alzheimer's is the ability to detect markers of the disease as early as possible. These markers, located in the brain, are difficult to access, hampering diagnosis. Using two types of llama antibody capable of crossing the blood-brain barrier, scientists from the Institut Pasteur, Inserm, the CNRS, the CEA, Pierre & Marie Curie and Paris Descartes Universities and Roche* have developed a non-invasive approach to reach brain cells in a mouse model of the disease. Once in the brain, these llama antibodies can specifically mark and show amyloid plaques and neurofibrillary tangles, the two types of lesions that characterize Alzheimer's disease. These results were published in the Journal of Controlled Release on October 7, 2016.

Alzheimer's disease is characterized by two types of cerebral lesion: amyloid plaques and neurofibrillary tangles. Amyloid beta peptide (Aβ), naturally present in the brain, builds up over the years as a result of genetic and environmental factors until it forms amyloid plaques. This build-up is toxic for nerve cells: it leads to a loss of neuronal structure and to what is known as "neurofibrillary" tangles (abnormal aggregation of the tau protein), which in turn results in cell death.

In this study, the team led by Pierre Lafaye, Head of the Antibody Engineering Platform in the Citech at the Institut Pasteur, in collaboration with the Chemistry of Biomolecules and Integrative Neurobiology of Cholinergic Systems Units from the Institut Pasteur and the CNRS, developed two new types of antibody capable of detecting the extracellular and intracellular targets (respectively amyloid plaques and neurofibrillary tangles) that are characteristic of Alzheimer's disease. To achieve this, they turned their attention to camelids, specifically llamas, since their small antibodies are easy to use. They used the variable region of the antibody, known as VHH or nanobodiesTM, to specifically recognize the markers of Alzheimer's.

These antibodies have the rare ability to cross the blood-brain barrier, which generally protects the brain from microbial attacks but also prevents potential therapeutic molecules from reaching it.

This collaborative research project, jointly conducted by scientists from the Institut Pasteur, Inserm, the CNRS, the CEA, Pierre & Marie Curie and Paris Descartes Universities and the Roche Group, led to the development of anti-Aβ and anti-tau protein antibodies that specifically detect amyloid plaques and neurofibrillary tangles. These antibodies were subsequently tested in vitro on the brain tissue of Alzheimer's patients.

The antibodies were then tested in vivo in two mouse models, each with one of the two characteristic lesions associated with Alzheimer's disease. These antibodies, labeled with a green fluorochrome, were injected intravenously and crossed the blood-brain barrier, binding to the two targets the scientists were aiming to identify: amyloid plaques and neurofibrillary tangles. This made the signs of the disease visible in the brain using two-photon microscopy. The scientists involved in this collaborative project are currently working on the development of an MRI imaging technique to observe the lesions. In the long term this could be applied to humans.

"Being able to diagnose Alzheimer's at an early stage could enable us to test treatments before the emergence of symptoms, something we were previously unable to do," explained Pierre Lafaye. These VHH antibodies could be used in combination with therapeutic molecules so that the molecules can be delivered in a targeted way to the brain.

Patents have been filed for these VHH antibodies and for their use based on their ability to cross the blood-brain barrier and bind to amyloid plaques and tau proteins.

###

This research was partly funded by the Roche Institute, the France Alzheimer Foundation and the Georges Pompidou Foundation.

Media Contact

Myriam Rebeyrotte
[email protected]

http://www.pasteur.fr

Share12Tweet7Share2ShareShareShare1

Related Posts

Five or more hours of smartphone usage per day may increase obesity

July 25, 2019
IMAGE

NASA’s terra satellite finds tropical storm 07W’s strength on the side

July 25, 2019

NASA finds one burst of energy in weakening Depression Dalila

July 25, 2019

Researcher’s innovative flood mapping helps water and emergency management officials

July 25, 2019
Next Post

How your diet can influence your environmental impact

WSU study reveals non-invasive prenatal genetic test is accurate five weeks into pregnancy

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    53 shares
    Share 21 Tweet 13
  • Blood pressure drug may be key to increasing lifespan, new study shows

    44 shares
    Share 18 Tweet 11
  • New drug form may help treat osteoporosis, calcium-related disorders

    38 shares
    Share 15 Tweet 10
  • New findings help explain how COVID-19 overpowers the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Climate ChangeChemistry/Physics/Materials SciencesBiologyInfectious/Emerging DiseasesTechnology/Engineering/Computer ScienceMedicine/HealthEcology/EnvironmentMaterialsGeneticscancerPublic HealthCell Biology

Recent Posts

  • Better diet and glucose uptake in the brain lead to longer life in fruit flies
  • Rapid blood test identifies COVID-19 patients at high risk of severe disease
  • Conductive nature in crystal structures revealed at magnification of 10 million times
  • Howard University professor to receive first Joseph A. Johnson Award
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In